|
|
|
|
|
|
|
|
abstract
Highlights
- •
- The decline in ovarian cancer mortality cannot be explained by a reduction in case-fatality
- •
- New treatments improve short-term survival and median survival, but not long-term survival or cure
In
the United States, the age-adjusted mortality rate from ovarian cancer
declined by 8% from 1975 to 1991 and by 18% from 1992 to 2011. A decline
in the incidence rate of ovarian cancer paralleled the decline in
mortality (described in Part I). The decline in mortality might also be
due to a reduced proportion of ovarian cancer patients who die from
their cancer (case-fatality). Here, we examine rates of ovarian cancer
case-fatality from the Surveillance Epidemiology and End Results (SEER)
registry database, and we consider to what extent advances in treatment
also contribute to the observed decline in mortality. From 1973 to 1999,
the five-year case-fatality rate for women with ovarian cancer fell by
7.5%, whereas the 12-year case-fatality rate fell by only 1.2%. The
declines in five-year case-fatality corresponded in time with the
introduction and expansion in use of cis-platinum and paclitaxel in
clinical practice. However, modest declines in 12-year case-fatality
indicate that the introduction of chemotherapy has not contributed to
the decline in mortality. Developments in the last two decades include
targeted therapies, aggressive surgical techniques, the use of
neoadjuvant chemotherapy and intraperitoneal chemotherapy. The impact of
these treatment modalities on ovarian cancer mortality still needs to
be evaluated.
I reposted this interesting information to Annie Appleseed Project's Facebook page. Thank you.
ReplyDelete